跳至主要内容
临床试验/JPRN-UMIN000019365
JPRN-UMIN000019365已完成未知

Dialyzability of faropenem sodium during hemodialysis in patients with chronic renal failure - Dialyzability of faropenem sodium during hemodialysis

Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University0 个研究点目标入组 10 人开始时间: 2015年10月17日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
10

研究概览

简要总结

The elimination ratio of faropenem by hemodialysis was small as about 20%; In the 29th Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics (Tokyo, Dec 4th -6th, 2008)

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. Patients with poorly controlled diabetes (HbA1c 7.0% or more) 2. Patients with hepatic failure 3. Patients have a history of allergy to beta-lactam antibiotics 4. Patients have been taking faropenem within one week 5. Patients taking sodium valproate 6. Patients taking warfarin 7. Pregnant women and nursing woman 8. Judged inappropriate to participate in this study by a doctor

研究者

发起方
Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University

相似试验